Want access to unlimited case records and advanced research tools? Create your free CasePortal account now. No credit card required to register.
Try CasePortal for FreeJ. Furman finds for the company in a securities fraud class action alleging that it made misrepresentations about its Contingent Value Rights issued along with its merger with another pharmaceutical company. The rights' value were tied to the FDA approval of certain drugs by strict deadlines. There is no evidence that senior corporate executives schemed to delay FDA approval of the drugs in order to avoid paying out investors in the contingent value rights.
To read this case, start your 14-day free trial.
Request a free trial account to get access to more case data, documents, and features.
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.